{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:36:12Z","timestamp":1794890172085,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zynbera Pharrmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s11689-019-9277-x","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T06:53:33Z","timestamp":1564728813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome"],"prefix":"10.1186","volume":"11","author":[{"given":"Helen","family":"Heussler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Silove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Tich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel O.","family":"Bonn-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Sebree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"9277_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ajhg.2013.09.013","volume":"93","author":"J Steinberg","year":"2013","unstructured":"Steinberg J, Webber C. The roles of FMRP-regulated genes in autism spectrum disorder: single- and multiple-hit genetic etiologies. Am J Hum Genet. 2013;93:825\u201339 Cell Press.","journal-title":"Am J Hum Genet"},{"key":"9277_CR2","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.2174\/1381612821666150914121038","volume":"21","author":"R Lozano","year":"2015","unstructured":"Lozano R, Martinez-Cerdeno V, Hagerman RJ. Advances in the understanding of the gabaergic neurobiology of FMR1 expanded alleles leading to targeted treatments for Fragile X Spectrum disorder. Curr Pharm Des. 2015;21:4972\u20139 NIH Public Access.","journal-title":"Curr Pharm Des"},{"key":"9277_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11689-010-9067-y","volume":"3","author":"L Cordeiro","year":"2011","unstructured":"Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord. 2011;3:57\u201367 BioMed Central.","journal-title":"J Neurodev Disord"},{"key":"9277_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci9020018","volume":"9","author":"J Weber","year":"2019","unstructured":"Weber J, Smith E, Berry-Kravis E, Cadavid D, Hessl D, Erickson C, et al. Voice of people with fragile X syndrome and their families: reports from a survey on treatment priorities. Brain Sci. 2019;9:1\u201313 Multidisciplinary Digital Publishing Institute.","journal-title":"Brain Sci"},{"key":"9277_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/00125817-200109000-00006","volume":"3","author":"DC Crawford","year":"2001","unstructured":"Crawford DC, Acu\u00f1a JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med. 2001;3:359\u201371 NIH Public Access.","journal-title":"Genet Med"},{"key":"9277_CR6","first-page":"1","volume":"3","author":"K-M Jung","year":"2012","unstructured":"Jung K-M, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3:1\u201311 Nature Publishing Group.","journal-title":"Nat Commun"},{"key":"9277_CR7","first-page":"153","volume":"30","author":"Z Mouslech","year":"2009","unstructured":"Mouslech Z, Valla V. Endocannabinoid system: an overview of its potential in current medical practice. Neuro Endocrinol Lett. 2009;30:153\u201379.","journal-title":"Neuro Endocrinol Lett"},{"key":"9277_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/pr.58.3.2","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58:389\u2013462 NIH Public Access.","journal-title":"Pharmacol Rev"},{"key":"9277_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","volume":"76","author":"PE Castillo","year":"2012","unstructured":"Castillo PE, Younts TJ, Ch\u00e1vez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76:70\u201381 Cell Press.","journal-title":"Neuron"},{"key":"9277_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conb.2014.03.017","volume":"29","author":"T Ohno-Shosaku","year":"2014","unstructured":"Ohno-Shosaku T, Kano M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol. 2014;29:1\u20138 Elsevier Current Trends.","journal-title":"Curr Opin Neurobiol"},{"key":"9277_CR11","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes MW, Kaczocha M, Berger WT, Leung KN, Ralph BP, Wang L, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem. 2015;290:8711\u201321.","journal-title":"J Biol Chem"},{"key":"9277_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.tips.2008.03.001","volume":"29","author":"V Di Marzo","year":"2008","unstructured":"Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci. 2008;29:229\u201333.","journal-title":"Trends Pharmacol Sci"},{"key":"9277_CR13","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1523\/JNEUROSCI.0795-10.2010","volume":"30","author":"L Zhang","year":"2010","unstructured":"Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci. 2010;30:5724\u20139 Society for Neuroscience.","journal-title":"J Neurosci"},{"key":"9277_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tp.2012.15","volume":"2","author":"F Leweke","year":"2012","unstructured":"Leweke F, Piomelli D, Pahlisch F, Muhl D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:1\u20137 Nature Publishing Group.","journal-title":"Transl Psychiatry"},{"key":"9277_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.bbr.2015.05.003","volume":"291","author":"M Qin","year":"2015","unstructured":"Qin M, Zeidler Z, Moulton K, Krych L, Xia Z, Smith CB. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome. Behav Brain Res. 2015;291:164\u201371 Elsevier.","journal-title":"Behav Brain Res"},{"key":"9277_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/can.2015.0008","volume":"1","author":"D Wei","year":"2016","unstructured":"Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment. Cannabis Cannabinoid Res. 2016;1:81\u20139 Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.","journal-title":"Cannabis Cannabinoid Res"},{"key":"9277_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","volume":"27","author":"MF Bear","year":"2004","unstructured":"Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27:370\u20137 Elsevier Current Trends.","journal-title":"Trends Neurosci"},{"key":"9277_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","volume":"119","author":"T Bakas","year":"2017","unstructured":"Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacol Res. 2017;119:358\u201370 Academic Press.","journal-title":"Pharmacol Res"},{"key":"9277_CR19","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","volume":"36","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients. Neuropsychopharmacology. 2011;36:1219\u201326 Springer Nature.","journal-title":"Neuropsychopharmacology"},{"key":"9277_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/can.2018.0053","volume":"4","author":"N Tartaglia","year":"2019","unstructured":"Tartaglia N, Bonn-Miller M, Hagerman R. Treatment of fragile X syndrome with cannabidiol: a case series study and brief review of the literature. Cannabis Cannabinoid Res. 2019;4:3\u20139.","journal-title":"Cannabis Cannabinoid Res"},{"key":"9277_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270\u20138.","journal-title":"Lancet Neurol"},{"key":"9277_CR22","first-page":"1","volume":"11","author":"C Rohleder","year":"2016","unstructured":"Rohleder C, M\u00fcller JK, Lange B, Leweke FM. Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence. Front Pharmacol. 2016;11:1\u201311 Frontiers.","journal-title":"Front Pharmacol"},{"key":"9277_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3109\/03639041003657295","volume":"36","author":"KS Paudel","year":"2010","unstructured":"Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. 2010;36:1088\u201397 Taylor & Francis.","journal-title":"Drug Dev Ind Pharm"},{"key":"9277_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/00004583-200209000-00006","volume":"41","author":"The Research Units On Pediatric Psychopharmacology Anxiety Study Group","year":"2002","unstructured":"The Research Units On Pediatric Psychopharmacology Anxiety Study Group. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry. 2002;41:1061\u20139 Elsevier.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"9277_CR25","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28\u201337 Matrix Medical Communications.","journal-title":"Psychiatry (Edgmont)"},{"key":"9277_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1023\/B:JADD.0000005999.27178.55","volume":"33","author":"AJ Esbensen","year":"2003","unstructured":"Esbensen AJ, Rojahn J, Aman MG, Ruedrich S. Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. J Autism Dev Disord. 2003;33:617\u201329 Kluwer Academic Publishers-Plenum Publishers.","journal-title":"J Autism Dev Disord"},{"key":"9277_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/BF01048240","volume":"22","author":"EC Marshburn","year":"1992","unstructured":"Marshburn EC, Aman MG. Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. J Autism Dev Disord. 1992;22:357\u201373 Kluwer Academic Publishers-Plenum Publishers.","journal-title":"J Autism Dev Disord"},{"key":"9277_CR28","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s10803-011-1370-2","volume":"42","author":"SM Sansone","year":"2012","unstructured":"Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42:1377\u201392 Springer US.","journal-title":"J Autism Dev Disord"},{"key":"9277_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1352\/1944-7558-119.1.1","volume":"119","author":"NM Russo-Ponsaran","year":"2014","unstructured":"Russo-Ponsaran NM, Yesensky J, Hessl D, Berry-Kravis E. Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale\u2014revised for fragile X syndrome. Am J Intellect Dev Disabil. 2014;119:1\u201316 501 3rd Street, NW Suite 200, Washington, D.C. 20001.","journal-title":"Am J Intellect Dev Disabil"},{"key":"9277_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","volume":"37","author":"JW Varni","year":"1999","unstructured":"Varni JW, Seid M, Rode CA. The PedsQL\u2122: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126\u201339.","journal-title":"Med Care"},{"key":"9277_CR31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/art.10095","volume":"46","author":"JW Varni","year":"2002","unstructured":"Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum. 2002;46:714\u201325 Wiley-Blackwell.","journal-title":"Arthritis Rheum"},{"key":"9277_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-8-57","volume":"8","author":"VS Williams","year":"2010","unstructured":"Williams VS, Morlock RJ, Feltner D. Psychometric evaluation of a visual analog scale for the assessment of anxiety. Health Qual Life Outcomes. 2010;8:1\u20138 BioMed Central.","journal-title":"Health Qual Life Outcomes"},{"key":"9277_CR33","volume-title":"ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"key":"9277_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.npp.1300873","volume":"31","author":"S Leucht","year":"2006","unstructured":"Leucht S, Engel RR. The relative sensitivity of the clinical global impressions scale and the brief psychiatric rating scale in antipsychotic drug trials. Neuropsychopharmacology. 2006;31:406\u201312 Nature Publishing Group.","journal-title":"Neuropsychopharmacology"},{"key":"9277_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/01.nmd.0000244554.91259.27","volume":"194","author":"GI Spielmans","year":"2006","unstructured":"Spielmans GI, McFall JP. A comparative meta-analysis of clinical global impressions change in antidepressant trials. J Nerv Ment Dis. 2006;194:845\u201352.","journal-title":"J Nerv Ment Dis"},{"key":"9277_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1017\/S0033291703007414","volume":"33","author":"TI Zaider","year":"2003","unstructured":"Zaider TI, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR. Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med. 2003;33:611\u201322 Cambridge University Press.","journal-title":"Psychol Med"},{"key":"9277_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11689-016-9181-6","volume":"9","author":"E Berry-Kravis","year":"2017","unstructured":"Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord. 2017;9:1\u201318 BioMed Central.","journal-title":"J Neurodev Disord"},{"key":"9277_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11689-017-9207-8","volume":"9","author":"A Ligsay","year":"2017","unstructured":"Ligsay A, Van Dijck A, Nguyen DV, Lozano R, Chen Y, Bickel ES, et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. J Neurodev Disord. 2017;9:1\u201313 BioMed Central.","journal-title":"J Neurodev Disord"},{"key":"9277_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00213-013-3289-0","volume":"231","author":"S Jacquemont","year":"2014","unstructured":"Jacquemont S, Berry-Kravis E, Hagerman R, Von Raison F, Gasparini F, Apostol G, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl). 2014;231:1237\u201350 Springer Berlin Heidelberg.","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-019-9277-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s11689-019-9277-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-019-9277-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T04:39:06Z","timestamp":1596256746000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-019-9277-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["9277"],"URL":"https:\/\/doi.org\/10.1186\/s11689-019-9277-x","relation":{},"ISSN":["1866-1947","1866-1955"],"issn-type":[{"value":"1866-1947","type":"print"},{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"10 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted under Good Clinical Practice (GCP) requirements. The Human Research Ethics Committees (HREC) reviewed and approved the protocol, informed consent form (ICF), patient information, and patient recruitment materials. This trial was designed and monitored in accordance with the procedures of the designated contract research organization (CRO), Covance Pty. Limited (North Ryde, Australia), that oversaw the study conduct. The study complied with the ethical principles of GCP as required by the major regulatory authorities and in accordance with the Declaration of Helsinki. Signed informed consent was obtained at Screening for all patients by their parent\/caregivers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HH, JC, and NS report no competing interests. WD is a consultant for Zynerba Pharmaceuticals. NT, CO, and TS are employees of Zynerba Pharmaceuticals. MBM was an employee of Zynerba Pharmaceuticals during the time of the study conduct and analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}